Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
cetuximab (CET) or bevacizumab (BV)
metastatic colorectal cancer
progression-free survival
quality of life
traditional Chinese medicine
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
11
2019
accepted:
26
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Huangci Granule is a traditional Chinese medicine for treating metastatic colorectal cancer (mCRC). To evaluate the efficacy and safety of Huangci Granule combination with chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC. We performed a randomized, controlled, and double-blind trial and recruited patients with mCRC who were planned to undergo chemotherapy combined with CET or BV. The treatment group was treated with Huangci Granule, while the control group was treated with placebo. Continuous treatment until disease progression, death, intolerable toxicity or up to 6 months. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was quality of life and safety. 320 patients were randomly assigned to receive treatment, including 200 first-line patients and 120 second-line patients. In the first-line treatment, the median PFS was 9.59 months (95% CI, 6.94-13.25) Huangci Granule combined with chemotherapy and CET or BV can prolong the PFS of mCRC, improve the quality of life, reduce adverse reactions, and have good safety.
Sections du résumé
BACKGROUND
BACKGROUND
Huangci Granule is a traditional Chinese medicine for treating metastatic colorectal cancer (mCRC).
OBJECTIVE
OBJECTIVE
To evaluate the efficacy and safety of Huangci Granule combination with chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC.
METHODS
METHODS
We performed a randomized, controlled, and double-blind trial and recruited patients with mCRC who were planned to undergo chemotherapy combined with CET or BV. The treatment group was treated with Huangci Granule, while the control group was treated with placebo. Continuous treatment until disease progression, death, intolerable toxicity or up to 6 months. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was quality of life and safety.
RESULT
RESULTS
320 patients were randomly assigned to receive treatment, including 200 first-line patients and 120 second-line patients. In the first-line treatment, the median PFS was 9.59 months (95% CI, 6.94-13.25)
CONCLUSION
CONCLUSIONS
Huangci Granule combined with chemotherapy and CET or BV can prolong the PFS of mCRC, improve the quality of life, reduce adverse reactions, and have good safety.
Identifiants
pubmed: 32372960
doi: 10.3389/fphar.2020.00478
pmc: PMC7187887
doi:
Types de publication
Journal Article
Langues
eng
Pagination
478Informations de copyright
Copyright © 2020 Liu, Wu, Jia, Cai, Wang, Zhou, Ji, Sui, Zeng, Xiao, Liu, Huo, Feng, Deng and Li.
Références
Cancer Lett. 2017 Sep 10;403:86-97
pubmed: 28602978
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Biosci Trends. 2015 Feb;9(1):16-34
pubmed: 25787906
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
J Clin Oncol. 2015 Nov 10;33(32):3718-26
pubmed: 26261259
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52):
pubmed: 29140496
JAMA Netw Open. 2019 Mar 1;2(3):e190896
pubmed: 30901045
Chin J Cancer Res. 2018 Feb;30(1):1-12
pubmed: 29545714
Can J Cardiol. 2014 May;30(5):534-43
pubmed: 24786444
Sci Transl Med. 2010 Aug 18;2(45):45ra59
pubmed: 20720216
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
N Engl J Med. 2004 Jul 22;351(4):337-45
pubmed: 15269313
J Clin Oncol. 2018 Oct 20;36(30):3031-3039
pubmed: 30199311
J Cancer. 2016 Sep 12;7(13):1877-1887
pubmed: 27698928
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Zhong Yao Cai. 2011 Feb;34(2):250-3
pubmed: 21823486
Planta Med. 2010 Aug;76(11):1118-31
pubmed: 20635308
J Clin Oncol. 2008 May 10;26(14):2311-9
pubmed: 18390971
Cancer Biother Radiopharm. 2017 Jun;32(5):149-160
pubmed: 28622036
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur J Cancer. 2003 Feb;39(3):287-94
pubmed: 12565979
Medicine (Baltimore). 2018 Nov;97(47):e13062
pubmed: 30461608
Acta Dermatovenerol Croat. 2016 Apr;24(1):70-2
pubmed: 27149134
Int J Pharm. 2019 Sep 10;568:118530
pubmed: 31323369
Health Qual Life Outcomes. 2011 Aug 22;9:70
pubmed: 21859485
J Clin Oncol. 2008 Oct 10;26(29):4828-33
pubmed: 18711170
Cancer Treat Rev. 2012 Aug;38(5):397-406
pubmed: 21899955
Skin Therapy Lett. 2017 Sep;22(5):5-7
pubmed: 28888217
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593